Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN011
MIFTS: 67

Adenoid Cystic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenoid Cystic Carcinoma

About this section

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 12 12 77 54 6 15 17 74
Salivary Gland Adenoid Cystic Carcinoma 12 56 15
Cylindroma 12 54
Adenoid Cystic Carcinoma of Salivary Gland 74
Carcinoma, Adenoid Cystic 45
Eccrine Dermal Cylindroma 74
Carcinoma Adenoid Cystic 56
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 54
Carcinoma, Cribriform 74
Cribriform Carcinoma 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Neuronal diseases Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080202 DOID:4866
MeSH 45 D003528
NCIt 51 C2970
SNOMED-CT 69 11671000
Sources

Summaries for Adenoid Cystic Carcinoma

About this section
NIH Rare Diseases : 54 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to prostate adenoid cystic carcinoma and lung adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Fentanyl and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia : 77 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Sources

Related Diseases for Adenoid Cystic Carcinoma

About this section

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 prostate adenoid cystic carcinoma 34.9 HRAS PIK3CA
2 lung adenoid cystic carcinoma 34.6 HRAS KIT KRAS NFIB PIK3CA
3 breast adenoid cystic carcinoma 34.6 ERBB2 KIT NFIB
4 prostate cancer 32.1 CCND1 CDH1 ERBB2 HRAS KRAS PIK3CA
5 pleomorphic adenoma 32.0 ERBB2 KRT14 TP53
6 polymorphous low-grade adenocarcinoma 31.8 CCND1 KIT MYB NFIB
7 adenocarcinoma 31.6 CCND1 CDH1 ERBB2 HRAS KIT KRAS
8 mucoepidermoid carcinoma 31.4 ERBB2 KRT14 KRT7
9 squamous cell carcinoma 31.3 CCND1 CDH1 ERBB2 HRAS NOTCH1 PIK3CA
10 small cell carcinoma 31.1 KIT KRT7 PTEN TP53
11 sarcoma 30.9 HRAS KIT KRAS PIK3CA TP53
12 gliosarcoma 30.9 IDH1 PTEN TP53
13 differentiated thyroid carcinoma 30.9 HRAS KRAS TP53
14 epithelial-myoepithelial carcinoma 30.8 FBXW7 HRAS KRT14 KRT7 TP53
15 teratoma 30.7 KIT KRT7 TP53
16 thyroid cancer 30.7 CCND1 CDH1 HRAS KIT KRAS PIK3CA
17 papillary carcinoma 30.7 CDH1 ERBB2 KRT7
18 sarcoma, synovial 30.7 CDH1 KIT KRT7
19 papilloma 30.6 CCND1 KRT14 KRT7 PTEN TP53
20 gastric cancer 30.6 CCND1 CDH1 ERBB2 KRAS PIK3CA PTEN
21 malignant spiradenoma 30.6 KRT7 PIK3CA TP53
22 spindle cell carcinoma 30.6 CDH1 KRT14 KRT7
23 carcinosarcoma 30.6 ERBB2 HRAS KIT KRAS KRT7 PIK3CA
24 glioblastoma 30.6 CCND1 ERBB2 HRAS IDH1 PIK3CA PTEN
25 basaloid squamous cell carcinoma 30.6 KRT14 KRT7 TP53
26 spiradenoma 30.5 CYLD KRT14 KRT7 TP53
27 nasopharyngeal carcinoma 30.5 CCND1 CDH1 HRAS PIK3CA STAT3 TP53
28 breast cancer 30.5 CCND1 CDH1 ERBB2 FBXW7 HRAS IDH1
29 squamous cell carcinoma, head and neck 30.5 CCND1 CDH1 ERBB2 HRAS PIK3CA PTEN
30 transitional cell carcinoma 30.5 CDH1 ERBB2 HRAS KRT7 PTEN TP53
31 sweat gland cancer 30.5 ERBB2 KRT14 KRT7 TP53
32 renal cell carcinoma, papillary, 1 30.4 ERBB2 HRAS KIT KRT7 PIK3CA PTEN
33 necrotizing sialometaplasia 30.4 KIT KRT7 TP53
34 lung cancer susceptibility 3 30.3 CCND1 CDH1 ERBB2 HRAS IDH1 KRAS
35 brooke-spiegler syndrome 30.2 CYLD KRT14 KRT7
36 lung cancer 30.2 CCND1 CDH1 ERBB2 HRAS KIT KRAS
37 hepatocellular carcinoma 30.1 CCND1 CDH1 HRAS IDH1 KRAS KRT7
38 cervical adenoid cystic carcinoma 12.8
39 maxillary sinus adenoid cystic carcinoma 12.6
40 lacrimal gland adenoid cystic carcinoma 12.6
41 trachea adenoid cystic carcinoma 12.6
42 laryngeal adenoid cystic carcinoma 12.5
43 esophageal adenoid cystic carcinoma 12.5
44 parotid gland adenoid cystic carcinoma 12.5
45 bartholin's gland adenoid cystic carcinoma 12.5
46 cribriform carcinoma 12.5
47 ethmoid sinus adenoid cystic carcinoma 12.4
48 cylindromatosis, familial 12.4
49 adenoid cystic carcinoma of the corpus uteri 12.3
50 sublingual gland adenoid cystic carcinoma 12.3

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma
Sources

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

27 (show top 50) (show all 63)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.6 KRAS HRAS PIK3CA
2 Decreased viability GR00106-A-0 10.6 KRAS
3 Decreased viability GR00221-A-1 10.6 CDH1 CYLD KIT KRAS HRAS PIK3CA
4 Decreased viability GR00221-A-2 10.6 CYLD KRAS HRAS PIK3CA
5 Decreased viability GR00221-A-3 10.6 HRAS
6 Decreased viability GR00221-A-4 10.6 PIK3CA
7 Decreased viability GR00301-A 10.6 CDH1 CYLD KIT KRAS
8 Decreased viability GR00381-A-1 10.6 KRAS
9 Decreased viability GR00402-S-2 10.6 CDH1 CYLD KIT KRAS HRAS PIK3CA
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.39 MYB
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.39 NFIB
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.39 KRAS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.39 NFIB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.39 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.39 KRAS MYB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.39 FBXW7 MYB
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.39 FBXW7 MYB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.39 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.39 MYB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.39 CCND1 FBXW7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.39 FBXW7 PIK3CA
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.39 CCND1 PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.39 MYB
24 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.39 CCND1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.39 MYB
26 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.39 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.39 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.39 MYB
29 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.39 CCND1 FBXW7 KRAS MYB NFIB PIK3CA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.39 FBXW7
31 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.39 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.39 KRAS
33 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.39 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.39 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.39 CCND1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.39 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.39 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.39 CCND1 NFIB
39 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.39 NFIB
40 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.39 CCND1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.39 PIK3CA
42 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.39 FBXW7
43 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.39 KRAS PIK3CA
44 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.39 KRAS
45 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.39 FBXW7
46 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.39 KRAS
47 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.39 MYB
48 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.39 MYB
49 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.39 MYB
50 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.39 KRAS

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 CCND1 CDH1 CYLD ERBB2 FBXW7 JAK3
2 endocrine/exocrine gland MP:0005379 10.51 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
3 growth/size/body region MP:0005378 10.51 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
4 homeostasis/metabolism MP:0005376 10.49 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
5 digestive/alimentary MP:0005381 10.47 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
6 mortality/aging MP:0010768 10.46 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
7 cardiovascular system MP:0005385 10.43 CCND1 CDH1 ERBB2 FBXW7 HRAS KIT
8 immune system MP:0005387 10.42 CCND1 CDH1 CYLD FBXW7 IDH1 JAK3
9 integument MP:0010771 10.41 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
10 hematopoietic system MP:0005397 10.38 CCND1 CYLD FBXW7 IDH1 JAK3 KIT
11 craniofacial MP:0005382 10.35 CCND1 ERBB2 FBXW7 HRAS KIT KRAS
12 embryo MP:0005380 10.33 CDH1 ERBB2 FBXW7 KIT KRAS MYB
13 neoplasm MP:0002006 10.32 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
14 nervous system MP:0003631 10.23 CCND1 ERBB2 FBXW7 HRAS KIT KRAS
15 normal MP:0002873 10.22 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
16 liver/biliary system MP:0005370 10.13 FBXW7 KIT KRAS MYB NOTCH1 PTEN
17 muscle MP:0005369 10.1 ERBB2 KIT KRAS NOTCH1 PIK3CA PTEN
18 respiratory system MP:0005388 10 CCND1 CYLD ERBB2 FBXW7 HRAS IDH1
19 no phenotypic analysis MP:0003012 9.98 CDH1 HRAS KIT KRAS MYB PIK3CA
20 reproductive system MP:0005389 9.96 CCND1 CDH1 ERBB2 KIT KRAS KRT14
21 renal/urinary system MP:0005367 9.92 HRAS KIT KRAS KRT7 NOTCH1 PTEN
22 pigmentation MP:0001186 9.85 KIT KRAS KRT14 NOTCH1 PTEN TP53
23 skeleton MP:0005390 9.7 CCND1 ERBB2 HRAS IDH1 KIT KRAS
24 vision/eye MP:0005391 9.36 CCND1 FBXW7 KIT KRAS KRT14 NFIB
Sources

Drugs & Therapeutics for Adenoid Cystic Carcinoma

About this section

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
3
Promethazine Approved, Investigational Phase 3 60-87-7 4927
4
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
5
Histamine Approved, Investigational Phase 3 51-45-6 774
6
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
7
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
8
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
9
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
10
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
11
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
12 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
13 Porfiromycin Investigational Phase 3 801-52-5
14 Cola Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
15 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
16 Anti-Infective Agents Phase 2, Phase 3,Phase 1
17 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
18 Central Nervous System Depressants Phase 3
19 Peripheral Nervous System Agents Phase 3,Not Applicable
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, Intravenous Phase 3
23 Narcotics Phase 3
24 Adjuvants, Anesthesia Phase 3
25 Analgesics Phase 3
26 Anesthetics, General Phase 3
27 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
30 Mitomycins Phase 3
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
32 Antidepressive Agents Phase 3
33
Histamine Phosphate Phase 3 51-74-1 65513
34 Neurotransmitter Agents Phase 3,Not Applicable
35 Psychotropic Drugs Phase 3
36 Antidepressive Agents, Tricyclic Phase 3
37 Histamine Antagonists Phase 3
38 Hypnotics and Sedatives Phase 3
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
40 Antifungal Agents Phase 2, Phase 3,Phase 1
41 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
42 Hormone Antagonists Phase 2, Phase 3
43 Hormones Phase 2, Phase 3,Phase 1
44 Steroid Synthesis Inhibitors Phase 2, Phase 3
45 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
46 Cholinergic Agents Phase 3,Not Applicable
47 Autonomic Agents Phase 3,Not Applicable
48 Muscarinic Agonists Phase 3
49 Antineoplastic Agents, Hormonal Phase 3
50 Appetite Stimulants Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
3 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
8 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
9 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Unknown status NCT00180921 Phase 2 Imatinib
11 Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
12 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
13 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02098538 Phase 2 Regorafenib
14 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT03087019 Phase 2 Pembrolizumab
15 Study of RAD001 in Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
16 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
17 A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Active, not recruiting NCT02775370 Phase 2 Apatinib Mesylate
18 Dovitinib in Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
19 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00581360 Phase 2 doxorubicin and bortezomib
20 Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
21 Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Active, not recruiting NCT02780310 Phase 2 Lenvatinib
22 Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Completed NCT01524692 Phase 2 Dovitinib (TKI258)
23 Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Recruiting NCT02942693 Phase 2 Apatinib
24 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Recruiting NCT02883374 Phase 2 Chidamide
25 Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) Recruiting NCT03639168 Phase 2 Chidamide combined with cisplatin
26 A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations Recruiting NCT03691207 Phase 2 AL101
27 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT01678105 Phase 2 Dovitinib
28 Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 Active, not recruiting NCT02860936 Phase 2 Lenvatinib
29 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed NCT01175980 Phase 2 Vorinostat
30 Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma Active, not recruiting NCT02859012 Phase 2 Axitinib
31 Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
32 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2 lapatinib ditosylate
33 Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
34 Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
35 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00859937 Phase 2 Dasatinib
36 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
37 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer Recruiting NCT03146650 Phase 2
38 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2 imatinib mesylate
39 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
40 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Active, not recruiting NCT02393820 Phase 2 pazopanib
41 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
42 Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study Not yet recruiting NCT03539172 Phase 2 Apatinib Mesylate
43 Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 Active, not recruiting NCT02857712 Phase 2 Axitinib
44 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Active, not recruiting NCT02123511 Phase 2 acetylcysteine
45 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
46 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
47 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
48 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Recruiting NCT03422679 Phase 1, Phase 2 CB-103
49 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
50 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Sources

Genetic Tests for Adenoid Cystic Carcinoma

About this section
Sources

Anatomical Context for Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

42
Salivary Gland, Breast, Lung, Trachea, Brain, Lymph Node, Cervix
Sources

Publications for Adenoid Cystic Carcinoma

About this section

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 2154)
# Title Authors Year
1
Long-term Outcomes of Globe-Preserving Surgery With Proton Beam Radiation for Adenoid Cystic Carcinoma of Lacrimal Gland. ( 30709640 )
2019
2
Adenoid Cystic Carcinoma of Buccal Mucosa: Role of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Detection and Biopsy of Pulmonary Metastases and Assessment of Treatment Response. ( 30713389 )
2019
3
The role of organ- and function-preserving radiotherapy in the treatment of adenoid cystic carcinoma of the larynx. ( 30723979 )
2019
4
Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cystic carcinoma of the lacrimal gland. ( 30728899 )
2019
5
Personalized Treatment for Lacrimal Sac Adenoid Cystic Carcinoma - Case Report and Literature Review. ( 30731273 )
2019
6
Role of apoptotic, autophagic and senescence pathways in minor salivary gland adenoid cystic carcinoma. ( 30736793 )
2019
7
Autophagy-related Gene Expression Regulated by HIF-1α in Salivary Adenoid Cystic Carcinoma. ( 30746817 )
2019
8
The value of MYB as a prognostic marker for adenoid cystic carcinoma: A meta-analysis. ( 30759319 )
2019
9
Adenoid cystic carcinoma with high-grade transformation forming spindle cell component of the submandibular gland. ( 30777403 )
2019
10
Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck. ( 30815724 )
2019
11
Combined surgery and radiotherapy as curative treatment for tracheal adenoid cystic carcinoma: a case report. ( 30836992 )
2019
12
Analysis of clinicopathological characteristics, MYB rearrangement and prognostic factors in salivary adenoid cystic carcinoma. ( 30854068 )
2019
13
Sympathetic innervation contributes to perineural invasion of salivary adenoid cystic carcinoma via the β2-adrenergic receptor. ( 30863115 )
2019
14
MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma. ( 30896785 )
2019
15
Pretreatment quantitative 18F-FDG PET/CT parameters as a predictor of survival in adenoid cystic carcinoma of the salivary glands. ( 30308429 )
2019
16
Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations. ( 30382367 )
2019
17
18 F-FDG PET/MRI vs MRI in patients with recurrent adenoid cystic carcinoma. ( 30548894 )
2019
18
PTEN downregulates WD repeat‑containing protein 66 in salivary adenoid cystic carcinoma. ( 30569117 )
2019
19
Distinctive clinicopathological features and disease‑specific survival of adenoid cystic carcinoma and adenoid basal carcinoma in the lower female genital tract. ( 30569173 )
2019
20
Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel BRAF Mutation. ( 30591482 )
2019
21
A rare case of nasopharyngeal adenoid cystic carcinoma treated with cetuximab-based induction therapy followed by concurrent chemoradiotherapy. ( 30594461 )
2019
22
Adenoid cystic carcinoma of the vagina: A case report. ( 30608403 )
2019
23
What are the multimode sonographic features of adenoid cystic carcinoma metastasized to the thyroid? ( 30614858 )
2019
24
Impact of lymph node sampling on survival in cN0 major salivary gland adenoid cystic carcinoma. ( 30620437 )
2019
25
Successful management of recurrent adenoid cystic carcinoma in the deep infratemporal fossa by maxillo-orbito-zygomatic approach. ( 30626547 )
2019
26
Lack of Deletion of 1p36 in 8 Cases of Primary Adenoid Cystic Carcinoma of the Skin. ( 30640762 )
2019
27
Adenoid cystic carcinoma of the sinonasal tract: a review of the national cancer database. ( 30645040 )
2019
28
The Role of Elective Neck Dissection in Patients With Adenoid Cystic Carcinoma of the Head and Neck. ( 30667061 )
2019
29
MIF promotes perineural invasion through EMT in salivary adenoid cystic carcinoma. ( 30667094 )
2019
30
Long-term Outcomes of Globe-Preserving Surgery Followed With Proton Beam Radiation for Adenoid Cystic Carcinoma of Lacrimal Gland. ( 30686477 )
2019
31
Adenoid cystic carcinoma of the breast. ( 30697408 )
2019
32
Computed tomographic features of adenoid cystic carcinoma in the palate. ( 30704527 )
2019
33
Cervical lymph node metastases in salivary gland adenoid cystic carcinoma: a systematic review and meta-analysis. ( 29970966 )
2018
34
Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study. ( 29850151 )
2018
35
Liver resection for metastases of tracheal adenoid cystic carcinoma: Report of two cases. ( 29778031 )
2018
36
Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. ( 29731974 )
2018
37
Central airway obstruction caused by adenoid cystic carcinoma in pregnancy: a case report and review of the literature. ( 29721318 )
2018
38
Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. ( 29710459 )
2018
39
Deregulation of Nicotinamide N-Methyltransferase and Gap Junction Protein Alpha-1 Causes Metastasis in Adenoid Cystic Carcinoma. ( 29277772 )
2018
40
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells. ( 29954240 )
2018
41
Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands. ( 29978608 )
2018
42
Discordant correlation of breast adenoid cystic carcinoma on imaging and pathology: A case report and literature review on surgical management. ( 29268125 )
2018
43
Potential biological functions of microvesicles derived from adenoid cystic carcinoma. ( 29725477 )
2018
44
Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis. ( 29399171 )
2018
45
3D-printing aided resection of intratracheal adenoid cystic carcinoma and mediastinal mature cystic teratoma in a 26-year-old female: a case report. ( 29607203 )
2018
46
miR-93-5p enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis by targeting BRMS1L. ( 29760585 )
2018
47
Dedifferentiated adenoid cystic carcinoma ex pleomorphic adenoma of the parotid. ( 29893347 )
2018
48
Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. ( 29858025 )
2018
49
IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-I_B/ZEB1 signaling pathway. ( 29885520 )
2018
50
Immunohistochemical Expression of CD-117 (c-KIT), P-53 and Ki-67 in Adenoid Cystic Carcinoma of Palate. ( 29866247 )
2018
Sources

Variations for Adenoid Cystic Carcinoma

About this section

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

6 (show top 50) (show all 118)
# Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
2 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
3 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
4 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
5 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
6 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
7 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
8 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
9 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
13 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
15 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
16 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192
17 CREBBP NM_004380.2(CREBBP): c.4336C> T (p.Arg1446Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs398124146 GRCh37 Chromosome 16, 3788618: 3788618
18 CREBBP NM_004380.2(CREBBP): c.4336C> T (p.Arg1446Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs398124146 GRCh38 Chromosome 16, 3738617: 3738617
19 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
20 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
21 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
22 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
23 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
24 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
25 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 GRCh37 Chromosome 19, 17947959: 17947959
26 JAK3 NM_000215.3(JAK3): c.1765G> A (p.Gly589Ser) single nucleotide variant Pathogenic rs886039394 GRCh38 Chromosome 19, 17837150: 17837150
27 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
28 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
29 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
30 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
31 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
32 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
33 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
34 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
35 PIK3CA NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 GRCh37 Chromosome 3, 178921553: 178921553
36 PIK3CA NM_006218.3(PIK3CA): c.1035T> A (p.Asn345Lys) single nucleotide variant Likely pathogenic rs121913284 GRCh38 Chromosome 3, 179203765: 179203765
37 CREBBP NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu) single nucleotide variant Likely pathogenic rs1057519884 GRCh37 Chromosome 16, 3788617: 3788617
38 CREBBP NM_004380.2(CREBBP): c.4337G> T (p.Arg1446Leu) single nucleotide variant Likely pathogenic rs1057519884 GRCh38 Chromosome 16, 3738616: 3738616
39 CREBBP NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His) single nucleotide variant Likely pathogenic rs1057519884 GRCh37 Chromosome 16, 3788617: 3788617
40 CREBBP NM_004380.2(CREBBP): c.4337G> A (p.Arg1446His) single nucleotide variant Likely pathogenic rs1057519884 GRCh38 Chromosome 16, 3738616: 3738616
41 CREBBP NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly) single nucleotide variant Likely pathogenic rs398124146 GRCh37 Chromosome 16, 3788618: 3788618
42 CREBBP NM_004380.2(CREBBP): c.4336C> G (p.Arg1446Gly) single nucleotide variant Likely pathogenic rs398124146 GRCh38 Chromosome 16, 3738617: 3738617
43 FBXW7 NM_001013415.2(FBXW7): c.1039C> T (p.Arg347Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh37 Chromosome 4, 153249385: 153249385
44 FBXW7 NM_001013415.2(FBXW7): c.1039C> T (p.Arg347Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh38 Chromosome 4, 152328233: 152328233
45 FBXW7 NM_001013415.2(FBXW7): c.1040G> A (p.Arg347His) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
46 FBXW7 NM_001013415.2(FBXW7): c.1040G> A (p.Arg347His) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
47 FBXW7 NM_001013415.2(FBXW7): c.1040G> C (p.Arg347Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
48 FBXW7 NM_001013415.2(FBXW7): c.1040G> C (p.Arg347Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232
49 FBXW7 NM_001013415.2(FBXW7): c.1040G> T (p.Arg347Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
50 FBXW7 NM_001013415.2(FBXW7): c.1040G> T (p.Arg347Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh38 Chromosome 4, 152328232: 152328232

Cosmic variations for Adenoid Cystic Carcinoma:

9 (show top 50) (show all 14045)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 0
2 COSM1658882 ZNF507 salivary gland,NS,carcinoma,adenoid cystic carcinoma c.34C>A p.P12T 19:32352864-32352864 0
3 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 0
4 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 0
5 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 0
6 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 0
7 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 0
8 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 0
9 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 0
10 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 0
11 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 0
12 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 0
13 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 0
14 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 0
15 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 0
16 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 0
17 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 0
18 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 0
19 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 0
20 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 0
21 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 0
22 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 0
23 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 0
24 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 0
25 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 0
26 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 0
27 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 0
28 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 0
29 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 0
30 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 0
31 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 0
32 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 0
33 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 0
34 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 0
35 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 0
36 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 0
37 COSM6982440 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 0
38 COSM6983995 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7133C>G p.T2378S 16:72795549-72795549 0
39 COSM6978013 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1855C>G p.H619D 16:72958291-72958291 0
40 COSM6962938 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4181C>A p.S1394* 16:72798501-72798501 0
41 COSM6937443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 0
42 COSM6845145 ZFHX3 salivary gland,major,carcinoma,NS c.8617G>A p.E2873K 16:72794065-72794065 0
43 COSM6953061 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10994A>T p.D3665V 16:72787282-72787282 0
44 COSM6953714 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3431G>T p.C1144F 16:72889748-72889748 0
45 COSM6969956 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.527G>T p.G176V 16:72959619-72959619 0
46 COSM4062722 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2486T>C p.M829T 16:72957660-72957660 0
47 COSM6939807 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 0
48 COSM6956103 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2437A>T p.T813S 16:72957709-72957709 0
49 COSM6826441 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 0
50 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 2:97737758-97737758 0

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma
Sources

Expression for Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.
Sources

Pathways for Adenoid Cystic Carcinoma

About this section

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 14.27 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
2
Innate Immune System 67
Show member pathways
 14.09 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
3
ERK Signaling 65
Show member pathways
 13.95 CCND1 CDH1 ERBB2 HRAS JAK3 KIT
4
GPCR Pathway 65
Show member pathways
 13.81 CCND1 ERBB2 HRAS JAK3 KIT KRAS
5
HIV Life Cycle 67
Show member pathways
 13.81 CDH1 ERBB2 FBXW7 HRAS IDH1 KIT
6
TGF-Beta Pathway 65
Show member pathways
 13.64 CDH1 ERBB2 HRAS JAK3 KIT KRAS
7
Developmental Biology 67
Show member pathways
 13.6 ERBB2 HRAS JAK3 KIT KRAS KRT14
8
Class I MHC mediated antigen processing and presentation 67
Show member pathways
 13.56 CDH1 ERBB2 FBXW7 HRAS KIT KRAS
9
Akt Signaling 65
Show member pathways
 13.51 CCND1 ERBB2 HRAS JAK3 KIT KRAS
10
Cytokine Signaling in Immune system 67
Show member pathways
 13.47 CCND1 ERBB2 HRAS JAK3 KIT KRAS
11
Response to elevated platelet cytosolic Ca2+ 67
Show member pathways
 13.4 HRAS JAK3 KRAS MYB PIK3CA SERPINA3
12
PAK Pathway 65
Show member pathways
 13.38 CDH1 ERBB2 HRAS KIT KRAS NOTCH1
13
IL-2 Pathway 65
Show member pathways
 13.32 CCND1 ERBB2 HRAS JAK3 KRAS PTEN
14
Human cytomegalovirus infection 38
Show member pathways
 13.07 CCND1 HRAS KRAS PIK3CA PTEN STAT3
15
Focal Adhesion 1 38
Show member pathways
 13.02 CCND1 ERBB2 HRAS KRAS PIK3CA PTEN
16
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13 ERBB2 HRAS KRAS PIK3CA PTEN STAT3
17
CCR5 Pathway in Macrophages 65
Show member pathways
 12.98 CCND1 HRAS JAK3 KRAS PIK3CA STAT3
18
NFAT and Cardiac Hypertrophy 65
Show member pathways
 12.98 ERBB2 HRAS JAK3 KRAS PIK3CA PTEN
19
PI3K-Akt signaling pathway 38
Show member pathways
 12.98 CCND1 ERBB2 HRAS JAK3 KIT KRAS
20
Endometrial cancer 38
Show member pathways
 12.9 CCND1 CDH1 ERBB2 HRAS KIT KRAS
21
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.89 CCND1 HRAS JAK3 KRAS PIK3CA PTEN
22
MAPK signaling pathway 1 38
12.85 ERBB2 HRAS KIT KRAS TP53
23
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.83 ERBB2 HRAS KIT KRAS PIK3CA PTEN
24
Ras signaling pathway 38
Show member pathways
 12.81 CDH1 HRAS KIT KRAS PIK3CA
25
Development HGF signaling pathway 23
Show member pathways
 12.79 CDH1 ERBB2 HRAS KRAS PIK3CA PTEN
26
4-1BB Pathway 65
Show member pathways
 12.76 HRAS JAK3 KRAS STAT3 TP53
27
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.75 CCND1 HRAS KRAS PIK3CA PTEN
28
Immune response IL-23 signaling pathway 23
Show member pathways
 12.72 ERBB2 HRAS KRAS PIK3CA STAT3 TP53
29
ErbB signaling pathway 1 38
Show member pathways
 12.7 CCND1 ERBB2 HRAS KRAS PIK3CA STAT3
30
Gastric cancer 38
Show member pathways
 12.69 CCND1 CDH1 ERBB2 HRAS KIT KRAS
31
NF-kappaB Signaling 4
12.67 CYLD JAK3 KIT MYB STAT3
32
Influenza A 38
Show member pathways
 12.66 CCND1 JAK3 PIK3CA STAT3 TP53
33
Pathways in cancer 38
12.66 CCND1 CDH1 ERBB2 HRAS JAK3 KIT
34
mTOR signaling pathway (KEGG) 66
Show member pathways
 12.62 ERBB2 HRAS KRAS PIK3CA PTEN TP53
35
Prolactin Signaling Pathway 1 38
Show member pathways
 12.6 CCND1 ERBB2 HRAS KRAS PIK3CA PTEN
36
Glioma 38
Show member pathways
 12.59 CCND1 CDH1 ERBB2 HRAS JAK3 KRAS
37
Apoptosis Pathway 73
Show member pathways
 12.56 ERBB2 HRAS KRAS PIK3CA TP53
38
MET promotes cell motility 67
Show member pathways
 12.54 HRAS KRAS PIK3CA STAT3
39
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.53 CCND1 HRAS JAK3 KRAS PIK3CA STAT3
40
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.52 HRAS JAK3 KRAS PIK3CA STAT3
41
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.51 CCND1 HRAS PIK3CA TP53
42
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.51 CDH1 ERBB2 HRAS KIT KRAS PIK3CA
43
MicroRNAs in cancer 38
12.5 CCND1 ERBB2 HRAS KRAS NOTCH1 PIK3CA
44
Phospholipase D signaling pathway 38
Show member pathways
 12.48 HRAS KIT KRAS PIK3CA
45
Development IGF-1 receptor signaling 23
Show member pathways
 12.48 CCND1 HRAS JAK3 PIK3CA PTEN STAT3
46
B cell receptor signaling pathway (KEGG) 38
Show member pathways
 12.46 HRAS KRAS PIK3CA PTEN
47
Human T-cell leukemia virus 1 infection 38
12.45 CCND1 HRAS JAK3 KRAS MYB PIK3CA
48
CNTF Signaling 65
Show member pathways
 12.42 HRAS JAK3 KRAS STAT3
49
Development A3 receptor signaling 23
Show member pathways
 12.41 CCND1 HRAS PIK3CA STAT3
50
B Cell Receptor Signaling Pathway (sino) 68
Show member pathways
 12.41 HRAS KRAS PIK3CA PTEN
Sources

GO Terms for Adenoid Cystic Carcinoma

About this section

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.83 CCND1 CYLD ERBB2 FBXW7 HRAS IDH1
2 cytoplasm GO:0005737 9.55 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
3 cytoplasmic side of plasma membrane GO:0009898 9.33 CDH1 KIT PTEN

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.92 HRAS KIT NOTCH1 STAT3
2 cell proliferation GO:0008283 9.91 ERBB2 HRAS PTEN STAT3 TP53
3 negative regulation of cell proliferation GO:0008285 9.91 HRAS NFIB NOTCH1 PTEN STAT3 TP53
4 positive regulation of protein phosphorylation GO:0001934 9.83 CCND1 ERBB2 HRAS KRAS
5 MAPK cascade GO:0000165 9.8 ERBB2 HRAS JAK3 KIT KRAS
6 positive regulation of cell proliferation GO:0008284 9.8 CCND1 HRAS KIT KRAS NOTCH1 PTEN
7 response to organic cyclic compound GO:0014070 9.78 CCND1 IDH1 PTEN STAT3
8 Ras protein signal transduction GO:0007265 9.77 HRAS KRAS TP53
9 response to organic substance GO:0010033 9.76 CCND1 CDH1 PTEN STAT3
10 positive regulation of epithelial cell proliferation GO:0050679 9.72 ERBB2 HRAS NOTCH1
11 positive regulation of Notch signaling pathway GO:0045747 9.67 KIT NOTCH1 STAT3
12 liver development GO:0001889 9.67 CCND1 KRAS NOTCH1 PIK3CA
13 regulation of mitochondrial membrane permeability GO:0046902 9.63 STAT3 TP53
14 response to leptin GO:0044321 9.63 CCND1 STAT3
15 cellular response to leptin stimulus GO:0044320 9.62 PTEN STAT3
16 positive regulation of MAP kinase activity GO:0043406 9.62 ERBB2 HRAS KIT KRAS
17 somatic stem cell division GO:0048103 9.61 KIT NOTCH1
18 interleukin-9-mediated signaling pathway GO:0038113 9.6 JAK3 STAT3
19 astrocyte differentiation GO:0048708 9.58 NOTCH1 STAT3
20 enzyme linked receptor protein signaling pathway GO:0007167 9.58 ERBB2 JAK3
21 interleukin-21-mediated signaling pathway GO:0038114 9.57 JAK3 STAT3
22 mitotic G1 DNA damage checkpoint GO:0031571 9.56 CCND1 TP53
23 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 FBXW7 HRAS KIT NOTCH1 PTEN
24 response to isolation stress GO:0035900 9.54 HRAS KRAS
25 cytokine-mediated signaling pathway GO:0019221 9.5 CCND1 JAK3 KIT KRAS PIK3CA STAT3
26 positive regulation of gene expression GO:0010628 9.23 ERBB2 HRAS KIT KRAS NOTCH1 PTEN
27 negative regulation of transcription by RNA polymerase II GO:0000122 10.08 CCND1 MYB NFIB NOTCH1 STAT3 TP53

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CCND1 CDH1 CYLD ERBB2 FBXW7 HRAS
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 MYB NFIB NOTCH1 STAT3 TP53
3 protein kinase binding GO:0019901 9.77 CCND1 CYLD PTEN STAT3 TP53
4 identical protein binding GO:0042802 9.7 CDH1 ERBB2 FBXW7 IDH1 PTEN STAT3
5 nucleotide binding GO:0000166 9.65 ERBB2 HRAS JAK3 KIT KRAS
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 ERBB2 KIT PIK3CA
7 protein phosphatase binding GO:0019903 8.92 ERBB2 JAK3 STAT3 TP53
Sources

Sources for Adenoid Cystic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....